Abstract
In pursuit of early therapeutic interventions for Parkinson’s disease, the proposed SynNeurGe classification system integrates α-synuclein pathology (S), neurodegeneration evidence (N), and pathogenic gene variants (G). This approach aims to address the disease’s complexity and biological diversity. It suggests categorizing patients based on the presence or absence of α-synuclein pathology in tissues or cerebrospinal fluid, neurodegeneration indicators from specific imaging techniques, and identification of pathogenic gene variants associated with Parkinson’s disease. The proposed system emphasizes the future need for precision medicine and aims to facilitate both basic and clinical research toward disease-modifying therapies. However, the authors stress that initial implementation should be confined to research settings, considering ethical implications and current limitations. Prospective validation of these criteria is deemed necessary to ensure their efficacy and ethical application in clinical practice.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin > Munich Cluster for Systems Neurology (SyNergy)
Medizin > Klinikum der LMU München > Neurologische Klinik und Poliklinik mit Friedrich-Baur-Institut |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
URN: | urn:nbn:de:bvb:19-epub-122898-6 |
ISSN: | 0300-9564 |
Sprache: | Englisch |
Dokumenten ID: | 122898 |
Datum der Veröffentlichung auf Open Access LMU: | 04. Dez. 2024 14:54 |
Letzte Änderungen: | 04. Dez. 2024 14:54 |
DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |